Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: the phase I TRIBE trial

Autor: Shohdy, K.S., Pillai, M., Abbas, K.S., Allison, J., Waddell, T., Darlington, E., Mohammad, S., Hood, S., Atkinson, S., Simpson, K., Morgan, D., Nathan, P., Kilgour, E., Dive, C., Thistlethwaite, F.

Publikováno v: In Immuno-Oncology and Technology June 2024 22

Meta-analysis informed machine learning: Supporting cytokine storm detection during CAR-T cell Therapy.

Autor: Bogatu A; Department of Computer Science, The University of Manchester, United Kingdom; Digital Experimental Cancer Medicine Team, Cancer Biomarker Centre, CRUK Manchester Institute, United Kingdom. Electronic address: alex.bogatu@manchester.ac.uk., Wysocka M; Digital Experimental Cancer Medicine Team, Cancer Biomarker Centre, CRUK Manchester Institute, United Kingdom., Wysocki O; Department of Computer Science, The University of Manchester, United Kingdom; Digital Experimental Cancer Medicine Team, Cancer Biomarker Centre, CRUK Manchester Institute, United Kingdom., Butterworth H; Cancer Biomarker Centre, CRUK Manchester Institute, United Kingdom., Pillai M; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, UK., Allison J; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, UK., Landers D; Digital Experimental Cancer Medicine Team, Cancer Biomarker Centre, CRUK Manchester Institute, United Kingdom., Kilgour E; Cancer Biomarker Centre, CRUK Manchester Institute, United Kingdom., Thistlethwaite F; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK., Freitas A; Department of Computer Science, The University of Manchester, United Kingdom; Digital Experimental Cancer Medicine Team, Cancer Biomarker Centre, CRUK Manchester Institute, United Kingdom; Idiap Research Institute, Switzerland.

Publikováno v: Journal of biomedical informatics [J Biomed Inform] 2023 Jun; Vol. 142, pp. 104367. Date of Electronic Publication: 2023 Apr 25.

Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.

Autor: Cani AK; Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.; Rogel Cancer Center, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA., Dolce EM; Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.; Rogel Cancer Center, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA., Darga EP; Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.; Rogel Cancer Center, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA., Hu K; Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.; Michigan Center for Translational Pathology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.; Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA., Liu CJ; Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.; Michigan Center for Translational Pathology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA., Pierce J; Cancer Research UK, Manchester Institute Cancer Biomarker Centre, University of Manchester, UK., Bradbury K; Cancer Research UK, Manchester Institute Cancer Biomarker Centre, University of Manchester, UK., Kilgour E; Cancer Research UK, Manchester Institute Cancer Biomarker Centre, University of Manchester, UK., Aung K; Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.; Rogel Cancer Center, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA., Schiavon G; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Carroll D; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Carr TH; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Klinowska T; Late Development, Oncology R&D, AstraZeneca, Cambridge, UK., Lindemann J; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Marshall G; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Rowlands V; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Harrington EA; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Barrett JC; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, MA, USA., Sathiyayogan N; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Morrow C; Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK., Sero V; Menarini Silicon Biosystems, Inc., San Diego, CA, USA., Armstrong AC; Department of Medical Oncology, The Christie NHS Foundation Trust and the Faculty of Biology, Medicine and Health, The University of Manchester, UK., Baird R; Breast Cancer and Early Phase Clinical Trials Teams, Cancer Research UK, Cambridge Centre, UK., Hamilton E; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN, USA., Im SA; Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea., Jhaveri K; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Patel MR; Sarah Cannon Research Institute/Florida Cancer Specialists, Sarasota, FL, USA., Dive C; Cancer Research UK, Manchester Institute Cancer Biomarker Centre, University of Manchester, UK., Tomlins SA; Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.; Michigan Center for Translational Pathology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA., Udager AM; Rogel Cancer Center, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.; Department of Pathology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.; Michigan Center for Translational Pathology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA., Hayes DF; Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.; Rogel Cancer Center, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA., Paoletti C; Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.; Rogel Cancer Center, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.

Publikováno v: Molecular oncology [Mol Oncol] 2022 May; Vol. 16 (10), pp. 1969-1985. Date of Electronic Publication: 2021 Dec 20.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.